Near miss materno em pacientes com lupus eritematoso sistêmico

Silva, Arlley Cleverson Belo da; Sun, Sue Yazaki; Campanharo, Felipe Favorette; Morooka, Letícia Tiemi; Cecatti, José Guilherme; Mattar, Rosiane

Acessibilidade / Reportar erro

Brasil

Revista Brasileira de Ginecologia e Obstetrícia

Español English

Brasil

Español English

sumário « anterior atual seguinte »

Sumário

Original Article • Rev Bras Ginecol Obstet. 45 (01) • Jan 2023 • https://doi.org/10.1055/s-0042-1759633 copiar

Near miss materno em pacientes com lupus eritematoso sistêmico

Autoria SCIMAGO INSTITUTIONS RANKINGS

Resumo

Objetivo

Lúpus eritematoso sistêmico (LES) pode causar danos irreversíveis aos órgãos. A gravidez com LES pode ter riscos para condições ameaçadoras à vida. O presente estudo teve como objetivo determinar a prevalência de MMG em pacientes com LES e analisar os parâmetros que contribuíram para os casos de maior gravidade.

Métodos

Trata-se de um estudo transversal retrospectivo a partir da análise de dados obtidos de prontuários de gestantes com LES atendidas em um Hospital Universitário no Brasil. As gestantes foram divididas em grupo controle sem intercorrências, grupo com condições potencialmente ameaçadoras a vida (CPAV) e grupo com near miss materno (NMM).

Resultados

A taxa de NMM foi de 112,9 por 1.000 nascidos vivos. A maioria dos casos de CPAV (83,9%) e NMM (92,9%) teve partos prematuros com risco aumentado estatisticamente significativo em comparação com o grupo controle (p = 0,0042; odds ratio [OR]: 12,05; intervalo de confiança [IC]: 1,5–96,6 para o grupo NMM e p = 0,0001; OR: 4,84; IC95%: 2,2–10,8 para o grupo CPAV). MMG aumenta o risco de maior tempo de internação (p < 0,0001; OR: 18,8; IC95%: 7,0–50,6 e p < 0,0001; OR: 158,17; IC95%: 17,6–1424,2 para os grupos CPAV e NMM, respectivamente), recémnascidos com baixo peso (p = 0,0006; OR: 3,67; IC95%: 1,7–7,9 e p = 0,0009; OR: 17,68; IC95%: 2–153,6 para os grupos CPAV e NMM, respectivamente), bem como doenças renais (CPAV: 58,9%; 33/56; p = 0,0069 e NMM: 78,6%; 11/14; p = 0,0026)]. Os casos de NMM apresentaram risco aumentado para óbito neonatal (p = 0,0128; OR: 38,4; IC95%: 3,3–440,3), natimorto e aborto espontâneo (p = 0,0011; OR: 7,68; IC95%: 2,2–26,3).

Conclusão

Lúpus eritematoso sistêmico foi significativamente associado à morbidade materna grave, internações mais longas e risco aumentado de desfechos obstétricos e neonatais ruins.

Palavras-chave
near miss materno; morbidade materna grave; lúpus eritematoso sistêmico; gravidez de alto risco; condições potencialmente ameaçadora à vida

Clinical criteria
Acute cyanosis	Loss of consciousness lasting 12 hours^e
Gasping^a	Loss of consciousness AND absence of pulse/heartbeat
Respiratory rate > 40 or < 6/min	Stroke^f
Shock^b	Uncontrollable fit/total paralysis^g
Oliguria nonresponsive to fluids or diuretics^c	Jaundice in the presence of pre-eclampsia^h
Clotting failure^d
Laboratory-based criteria
Oxygen saturation < 90% for ≥ 60 minutes	pH < 7.1
PaO2/FiO2 < 200mmHg	Lactate > 5
Creatinine ≥ 300 mmol/l or ≥ 3,5 mg/dl	Acute thrombocytopenia (< 50,000 platelets)
Bilirubin >100 µmol/l or > 6,0 mg/dl	Loss of consciousness AND the presence of glucose and ketoacids in urine
Management-based criteria
Use of continuous vasoactive drugsⁱ	Intubation and ventilation for 60 minutes not related to anesthesia
Hysterectomy following infection or hemorrhage	Dialysis for acute renal failure
Transfusion of ≥ 5 units red cell transfusion	Cardiopulmonary resuscitation (CPR)

Hemorrhagic disorders	Hypertensive disorders
Abruptio placenta	Severe pre-eclampsia
Accreta/increta/percreta placenta	Eclampsia
Ectopic pregnancy	Severe hypertension
Postpartum hemorrhage	Hypertensive encephalopathy
Ruptured uterus	HELLP syndrome
Other systemic disorders	Severe management indicators
Endometritis	Blood transfusion
Pulmonary edema	Central venous access
Respiratory failure	Hysterectomy
Seizures	ICU admission
Sepsis	Prolonged hospital stay (> 7 postpartum days)
Shock	Non anesthetic intubation
Thrombocytopenia < 100,000	Return to operating room
Thyroid crisis	Surgical intervention

Characteristics	Group			p-value	p-value
Characteristics	PLTC	MNM	Control Group	Control Group PLTC	Control Group MNM
Age (years old)
15 to 25	16 (28.6%)	9 (64.3%)	25 (31,6%)	0.2335^c	0.0647^a
26 to 35	34 (60.7%)	4 (28.6%)	38 (48,1%)
> 35	6 (10.7%)	1 (7.1%)	16 (20,3%)
(n)	56	14	79
Ethnic origin^d
White	34 (66.7%)	9 (75%)	37 (53.6%)	0.1507^c	0.1677^c
Other	17 (33.3%)	3 (25%)	32 (46.4%)
(n)	51	12	69
Education^e
None	6 (11.3%)	2 (18.2%)	9 (15%)	0.9241^c	0.9121^a
Primary school	14 (26.4%)	2 (18.2%)	17 (28.3%)
High school	28 (52.8%)	6 (54.5%)	29 (48.3%)
University	5 (9.4%)	1 (9.1%)	5 (8.3%)
(n)	53	11	60
Marital status^f
With partner	42 (79.2%)	9 (69.2%)	50 (69.4%)	0.2193^c	1.0000^b
No partner	11 (20.8%)	4 (30.8%)	22 (30.6%)
(n)	53	13	72
Number of pregnancies
1	25 (44.6%)	6 (42.9%)	24 (30.4%)	0.0895^c	0.3679^b
≥ 2	31 (55.4%)	8 (57.1%)	55 (69.6%)
(n)	56	14	79
Parity
0	29 (51.8%)	6 (42.9%)	31 (39.2%)	0.1484^c	0.7989^c
≥ 1	27 (48.2%)	8 (57.1%)	48 (60.8%)
(n)	56	14	79
Prenatal visits
0	8 (14.3%)	6 (42.9%)	15 (19%)	0.1638^a	0.0549 ^a
1–5	12 (21.4%)	4 (28.6%)	14 (17.7%)
6–12	25 (44.6%)	4 (28.6%)	41 (51.9%)
13–18	8 (14.3%)	0 (0%)	9 (11.4%)
> 18	3 (5.4%)	0 (0%)	0 (0%)
(n)	56	14	79

Patient	Age (years old)	Criteria
		Clinical	Laboratory	Management
Case 1	31	–	–	Hysterectomy following infection or hemorrhage
Case 2	28	Shock	–	Transfusion of ≥ 5 units of red cells
Case 3	25	Clotting failure	Lactate > 5 / Platelets < 50,000	Transfusion of ≥ 5 units of red cells
Case 4	20	–	–	Transfusion of ≥ 5 units of red cells
Case 5	24	Respiratory rate > 40 or < 6/min	Lactate > 5	–
Case 6	24	–	Oxygen saturation < 90% for ≥ 60 minutes/Lactate > 5	Intubation/ventilation for ≥ 60 min not related to anesthesia
Case 7	22	–	Creatinine ≥ 3.5mg/dl	Dialysis for acute renal failure
Case 8	32	–	Creatinine ≥ 3.5mg/dl	Dialysis for acute renal failure
Case 9	37	–	Creatinine ≥ 3.5mg/dl	Dialysis for acute renal failure
Case 10	25	–	Creatinine ≥ 3.5mg/dl	Dialysis for acute renal failure
Case 11	27	–	Creatinine ≥ 3.5mg/dl	–
Case 12	19	–	–	Dialysis for acute renal failure
Case 13	22	–	Creatinine ≥ 3.5mg/dl/ Lactate > 5	–
Case 14	22	–	Lactate > 5	–

Characteristics	Group		p-value	OR (95% CI)
Characteristics	PLTC	Control Group
Hospital Stay (days)			< 0.0001	18.8 [7.0–50.6]
< 8 (ref)	22 (39.3%)	73 (92.4%)
≥ 8	34 (60.7%)	6 (7.6%)
(n)	56	79
GA at delivery (weeks)			0.0001	4.84 [2.2–10.8]
< 37	47 (83.9%)	41 (51.9%)
≥ 37 (ref)	9 (16.1%)	38 (48.1%)
(n)	56	79
Outcome/Mode of delivery
Miscarriage	1 (1.9%)	12 (15.2%)	0.1301^a	5.78 [0.7–49.3]
Cesarean section	41 (74.5%)	40 (50.6%)	0.0774	0.47 [0.2–1.0]
Vaginal (ref)	13 (23.6%)	27 (34.2%)		–
(n)	55^b	79
Neonatal outcome
Neonatal death < 7 days	4 (7.5%)	0 (0%)	0.0975^a	12.84 [0.2–57.7]
Neonatal death ≥ 7 days	2 (3.8%)	0 (0%)	0.5275^a	7.13 [0.1–25843.3]
Miscarriage/stillbirth	3 (5.7%)	14 (18.2%)	0.1916	0.31 [0.083–1.1]
Hospital discharge (ref)	44 (83%)	63 (81.8%)		–
(n)	53	77
Birthweight (grams)
≤ 2,500	32 (59.3%)	19 (28.4%)	0.0006	3.67 [1.7–7.9]
> 2,500	22 (40.7%)	48 (71.6%)
(n)	54^c	67^d

Characteristics	Group		p-value	OR (95% CI)
Characteristics	MNM	Control Group
Hospital Stay (days)			< 0.0001	158.17 [17.6– 1424.2]
< 8 (ref)	1 (7.1%)	73 (92.4%)
≥ 8	13 (92.9%)	6 (7.6%)
(n)	14	79
GA at delivery (weeks)			0.0042	12.05 [1.5–96.6]
< 37	13 (92.9%)	41 (51.9%)
≥ 37 (ref)	1 (7.1%)	38 (48.1%)
(n)	14	79
Outcome/mode of delivery
Miscarriage	6 (42.9%)	12 (15.2%)	0.0899^a	0.22 [0.05–1.04]
Cesarean section	5 (35.7%)	40 (50.6%)	0.5687	0.89 [0.20–4.0]
Vaginal (ref)	3 (21.4%)	27 (34.2%)		–
(n)	14	79
Neonatal outcome
Neonatal death ≥ 7 days	2 (14.3%)	0 (0%)	0.0128^a	38.4 [3.3–440.3]
Miscarriage/stillbirth	8 (57.1%)	14 (18.2%)	0.0011	7,68 [2.2–26.3]
Hospital discharge (ref)	4 (28.6%)	63 (81.8%)
(n)	14	77
Birthweight (grams)
≤ 2,500	7 (87.5%)	19 (28.4%)	0.0009	17,68 [2–153.6]
> 2,500	1 (12.5%)	48 (71.6%)
(n)	8^b	67^c

	Group			p-value	p-value
Systemic impairment	PLTC	MNM	Control Group	Control Group PLTC	Control Group MNM
	n = 56	n = 14	n = 79	Control Group PLTC	Control Group MNM
Renal disorder	33 (58.9%)	11 (78.6%)	28 (35.4%)	0.0069	0.0026
Cutaneous disorder	36 (64.3%)	9 (64.3%)	65 (82.3%)	0.0177	0.1521 ^a
Arthritis	39 (69.6%)	9 (64.3%)	57 (72.2%)	0.7513	0.5385 ^a
Serositis	11 (19.6%)	2 (14.3%)	13 (16.5%)	0.6332	1.0000 ^a
Blood disorder	28 (50%)	10 (71.4%)	32 (40.5%)	0.2741	0.0321
Neurologic disorder	4 (7.1%)	3 (21.4%)	8 (10.1%)	0.7606^a	0.3619^a
Antibodies
Anti DNA	19 (33.9%)	3 (21.4%)	21 (26.6%)	0.3571	1.0000^a
Anti Smith (Sm)	10 (17.9%)	2 (14.3%)	15 (19%)	0.8677	1.0000 ^a
Anticardiolipin	11 (19.6%)	1 (7.1%)	6 (7.6%)	0.0376	1.0000 ^a
Lupus anticoagulant	4 (7.1%)	1 (7.1%)	0 (0%)	0.0278 ^a	0.1505 ^a
Anti Ro	15 (26.8%)	2 (14.3%)	27 (34.2%)	0.3607	0.2120 ^a
Anti La	4 (7.1%)	0 (0%)	5 (6.3%)	1.0000 ^a	1.0000 ^a
Antinuclear	47 (83.9%)	11 (78.6%)	62 (78.5%)	0.4291	1.0000 ^a
Anti RNP	14 (25%)	3 (21.4%)	20 (25.3%)	0.9667	1.0000 ^a

Federação Brasileira das Sociedades de Ginecologia e Obstetrícia Av. Brigadeiro Luís Antônio, 3421, sala 903 - Jardim Paulista, 01401-001 São Paulo SP - Brasil, Tel. (55 11) 5573-4919 - Rio de Janeiro - RJ - Brazil
E-mail: editorial.office@febrasgo.org.br

Acompanhe os números deste periódico no seu leitor de RSS

[1] Address for correspondence A Arlley Cleverson Belo da Silva, Rua Napoleão de Barros, 875, 04024-002, Vila Clementino, São Paulo, SP, Brazil (e-mail: arlleyc@hotmail.com).